Evidence map›Paper›PMID 22733664›Full record

ArticleProtein science : a publication of the Protein Society2012

Protein flexibility is key to cisplatin crosslinking in calmodulin.

Huilin Li, Stephen A Wells, J Emilio Jimenez-Roldan, Rudolf A Römer, Yao Zhao, Peter J Sadler, Peter B O'Connor

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Simultaneous mass spectrometry analysis of cisplatin with oligonucleotide-peptide mixtures: implications for the mechanism of action.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. 2D FT-ICR MS of Calmodulin: A Top-Down and Bottom-Up Approach.Journal of the American Society for Mass Spectrometry · 2016
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Huilin LiDepartment of Chemistry, University of Warwick, Coventry CV4 7AL, United Kingdom.
Stephen A Wells
J Emilio Jimenez-Roldan
Rudolf A Römer
Yao Zhao
Peter J Sadler
Peter B O'Connor
University of Warwick · GB

Funding

Defining the IsoAspartomeR01GM078293 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LIN, CHENG · 2007 to 2011
$1.5M
European Research Council 247450NIGMS NIH HHS R01 GM078293NIGMS NIH HHS R01GM078293
6 · The paper itself

Abstract

Chemical crosslinking in combination with Fourier transform ion cyclotron resonance mass spectrometry (FTICR MS) has significant potential for studying protein structures and protein-protein interactions. Previously, cisplatin has been shown to be a crosslinker and crosslinks multiple methionine (Met) residues in apo-calmodulin (apo-CaM). However, the inter-residue distances obtained from nuclear magnetic resonance structures are inconsistent with the measured distance constraints by crosslinking. Met residues lie too far apart to be crosslinked by cisplatin. Here, by combining FTICR MS with a novel computational flexibility analysis, the flexible nature of the CaM structure is found to be key to cisplatin crosslinking in CaM. It is found that the side chains of Met residues can be brought together by flexible motions in both apo-CaM and calcium-bound CaM (Ca₄-CaM). The possibility of cisplatin crosslinking Ca₄-CaM is then confirmed by MS data. Therefore, flexibility analysis as a fast and low-cost computational method can be a useful tool for predicting crosslinking pairs in protein crosslinking analysis and facilitating MS data analysis. Finally, flexibility analysis also indicates that the crosslinking of platinum to pairs of Met residues will effectively close the nonpolar groove and thus will likely interfere with the binding of CaM to its protein targets, as was proved by comparing assays for cisplatin-modified/unmodified CaM binding to melittin. Collectively, these results suggest that cisplatin crosslinking of apo-CaM or Ca₄-CaM can inhibit the ability of CaM to recognize its target proteins, which may have important implications for understanding the mechanism of tumor resistance to platinum anticancer drugs.

Indexed as

AnimalsBinding SitesCalmodulinCattleCisplatinCross-Linking ReagentsFourier AnalysisMass SpectrometryMelittenModels, MolecularNuclear Magnetic Resonance, BiomolecularProtein BindingProtein ConformationCalmodulinCisplatinCross-Linking ReagentsMelitten

Identifiers

PMID22733664
PMCPMC3631356
OpenAlexW2081503971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.